Age‑dependent extracellular matrix remodeling skews Shh gradient formation and dictates regenerative outcome

Grant Danielsen· Mar 21, 2026

Mechanism: Aged extracellular matrix (ECM) sequesters Shh ligand, leading to reduced GLI activator and increased GLI3 repressor signaling, impairing tissue regeneration. Readout: Readout: Heparanase and collagen-crosslink breakers restore Shh gradient, increase satellite cell proliferation and capillary density, and rescue muscle force recovery to 80% of young levels.

Hypothesis

In aged tissues, fibrosis‑associated changes in extracellular matrix (ECM) composition and heparan sulfate proteoglycan (HSPG) sulfation sequester Hedgehog (Shh) ligand, shortening its effective diffusion range. This produces a shallow GLI activator gradient and a relative increase in GLI3 repressor (GLI3R) signaling, which impairs the spatial cues needed for satellite cell activation and angiogenesis. Restoring ECM permeability or altering HSPG sulfation should re‑establish a physiological Shh gradient and rescue regeneration.

Mechanistic Basis

Ligand sequestration: Aged ECM shows elevated collagen cross‑linking and increased heparan sulfate 6‑O‑sulfation, both known to bind Shh with high affinity (PMID: 29563312). Bound ligand cannot freely diffuse, creating a local sink near the source.
PTCH1 dynamics: PTCH1 acts as a secondary sink; its expression rises with age (PMC12992551), further lowering free Shh concentration downstream.
GLI processing: Lower Shh levels reduce GLI2/GLI3 activator formation while favoring GLI3R processing via constitutive PKA/CK1/GSK3β activity, steepening the repressor/activator ratio.
Feedback: Reduced GLI1 transcription diminishes positive feedback on pathway components, locking the system in a low‑activity state.

Predictions & Experimental Design

Gradient measurement: Use a Gli1‑lacZ or Gli2‑GFP reporter in young (3 mo) and aged (24 mo) mice after intramuscular Shh‑protein or SAG injection. Quantify spatial fluorescence intensity at 0‑2 mm from the injection site. Prediction: aged muscle will show a flatter gradient (reduced slope) and higher basal GLI3R‑dependent reporter activity.
ECM modulation: Co‑inject heparanase (to cleave HSPG) or a collagen‑crosslink breaker (e.g., β‑aminopropionitrile) with Shh. Prediction: heparanase treatment will steepen the GLI gradient in aged tissue to youthful levels and improve satellite cell proliferation (Pax7+ Ki67+) and capillary density (CD31+).
Component quantification: Perform quantitative Western blot or mass‑spec for Shh, PTCH1, SMO, GLI1‑3, and GLI3R in microdissected regeneration zones. Prediction: aged tissue will have higher PTCH1 and HSPG‑bound Shh fractions, lower free Shh, and an elevated GLI3R/GLI1 ratio.
Functional read‑out: Assess muscle force recovery after injury (e.g., cardiotoxin) with the above interventions. Prediction: only conditions that restore the gradient (heparanase + Shh) will rescue torque to ~80 % of young controls.

Potential Outcomes

Supportive data: Observation of a rescued GLI gradient correlating with improved regeneration would confirm that ECM‑mediated ligand sequestration is a key age‑dependent lesion in Shh signaling.
Refuting data: If heparanase fails to alter the gradient or regeneration despite reducing HSPG staining, then other mechanisms (e.g., altered SMO ciliary trafficking) must dominate, redirecting focus to receptor‑level defects.

Hypothesis

Mechanistic Basis

Ligand sequestration: Aged ECM shows elevated collagen cross‑linking and increased heparan sulfate 6‑O‑sulfation, both known to bind Shh with high affinity (PMID: 29563312). Bound ligand cannot freely diffuse, creating a local sink near the source.

PTCH1 dynamics: PTCH1 acts as a secondary sink; its expression rises with age (PMC12992551), further lowering free Shh concentration downstream.

GLI processing: Lower Shh levels reduce GLI2/GLI3 activator formation while favoring GLI3R processing via constitutive PKA/CK1/GSK3β activity, steepening the repressor/activator ratio.

Feedback: Reduced GLI1 transcription diminishes positive feedback on pathway components, locking the system in a low‑activity state.

Predictions & Experimental Design

Gradient measurement: Use a Gli1‑lacZ or Gli2‑GFP reporter in young (3 mo) and aged (24 mo) mice after intramuscular Shh‑protein or SAG injection. Quantify spatial fluorescence intensity at 0‑2 mm from the injection site. Prediction: aged muscle will show a flatter gradient (reduced slope) and higher basal GLI3R‑dependent reporter activity.

ECM modulation: Co‑inject heparanase (to cleave HSPG) or a collagen‑crosslink breaker (e.g., β‑aminopropionitrile) with Shh. Prediction: heparanase treatment will steepen the GLI gradient in aged tissue to youthful levels and improve satellite cell proliferation (Pax7+ Ki67+) and capillary density (CD31+).

Component quantification: Perform quantitative Western blot or mass‑spec for Shh, PTCH1, SMO, GLI1‑3, and GLI3R in microdissected regeneration zones. Prediction: aged tissue will have higher PTCH1 and HSPG‑bound Shh fractions, lower free Shh, and an elevated GLI3R/GLI1 ratio.

Functional read‑out: Assess muscle force recovery after injury (e.g., cardiotoxin) with the above interventions. Prediction: only conditions that restore the gradient (heparanase + Shh) will rescue torque to ~80 % of young controls.

Potential Outcomes

Supportive data: Observation of a rescued GLI gradient correlating with improved regeneration would confirm that ECM‑mediated ligand sequestration is a key age‑dependent lesion in Shh signaling.

Refuting data: If heparanase fails to alter the gradient or regeneration despite reducing HSPG staining, then other mechanisms (e.g., altered SMO ciliary trafficking) must dominate, redirecting focus to receptor‑level defects.